Kansas City Partners Launch Integrated Theranostics Platform for Adult and Pediatric Patients
核心洞察
The University of Kansas Health System, University of Kansas Medical Center, Children's Mercy (搜索), and BAMF Health announced plans to establish one of the nation's first fully integrated theranostics platforms serving both adult and pediatric patients.
The collaboration will create a state-of-the-art facility housing radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials in one location.
Children's Mercy (搜索) represents one of the first pediatric health systems to invest early in theranostics technology, ensuring children access to this precision medicine approach.
Grand Rapids-based BAMF Health has partnered with three major Kansas City healthcare organizations to establish one of the nation's first fully integrated theranostics platforms designed for both adult and pediatric patients. The collaboration brings together The University of Kansas Health System, University of Kansas Medical Center, and Children's Mercy (搜索) to create a comprehensive precision medicine facility in Missouri.
Precision Medicine Approach
Theranostics represents a precision medicine approach that employs the same targeting system to both locate and treat disease in the body using radiopharmaceuticals (搜索). By delivering radiation directly to diseased cells, the technology treats disease more precisely, minimizes damage to healthy tissue, and results in fewer side effects compared to conventional treatments.
"Theranostics is redefining what's possible in the fight against devastating diseases," said BAMF Health Founder and CEO Anthony Chang, PhD. "BAMF Health is leading the way in bringing this advanced technology to every single patient who needs it around the globe. This meaningful collaboration advances our mission to give patients more time, more hope, and more meaningful moments with their loved ones."
Comprehensive Integrated Platform
The new facility will establish a vertically integrated theranostics approach, allowing radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials to occur in the same location. This integration represents a significant advancement in how theranostic treatments are delivered and researched.
Currently, The University of Kansas Cancer Center offers theranostic treatments for certain types of metastatic prostate cancer (搜索) and neuroendocrine cancer (搜索). The collaboration will significantly expand these capabilities across multiple disease areas.
Expanding Clinical Applications
The partnership aims to broaden access to cutting-edge clinical trials, therapies, and diagnostics across multiple diseases. According to Matthias Salathe, M.D., chief research officer for the University of Kansas, the number of clinical trials in radiopharmaceuticals (搜索) is growing exponentially, including applications in neurologic conditions such as Alzheimer's disease (搜索).
"Through this collaboration, we can offer our patients access to promising, cutting-edge investigational agents through participation in clinical trials," Salathe said.
Pediatric Innovation
Children's Mercy (搜索) represents one of the first pediatric health systems to invest early in theranostics technology, addressing a significant gap in the field. While theranostics is currently used almost exclusively in adult care, this collaboration ensures children will not be left behind as the field rapidly advances.
"At Children's Mercy (搜索), we believe the future of pediatric care is built through bold collaborations and a shared commitment to what's possible," said Alejandro Quiroga, M.D., MBA, president and CEO. "By joining forces with The University of Kansas Health System, the University of Kansas Medical Center and BAMF Health, we are taking a decisive step toward redefining how children access the most advanced care."
Regional Healthcare Impact
The collaboration is expected to drive significant investment in the Kansas City region as a destination for healthcare and research. Bob Page, president and CEO of The University of Kansas Health System, described theranostics as "the next forefront of precision medical care and research."
"This collaboration will advance both discovery and treatment, while driving investment in the Kansas City region as a destination for healthcare and research," Page said.
Steve Stites, M.D., executive vice chancellor for KU Medical Center and chief health sciences officer for KU, emphasized the potential for rapid delivery of unique radiopharmaceutical clinical trials based on cutting-edge science and drug development efforts taking place onsite at KU Medical Center.